Company intelligence / Profile preview

Shenzhen Resproly Biopharmaceutical

Zhuhai, Guangdong, Chinaen.resproly.com ↗

Ownership: Private
Development stage: Other

Overview

Resproly has advanced its lead asset RSN0402, an innovative inhaled powder therapy for idiopathic pulmonary fibrosis, into Phase 1 clinical trials in Australia and the United States. Preclinical studies showed safety and efficacy in reducing lung fibrosis and inflammation. The company is also developing a pipeline of complex generic and novel drugs for respiratory diseases using its proprietary EDDIP platform[6].

Therapeutic areas: PulmonologyCardiovascularNeurology
Modalities: Small moleculeInhalation therapy (includes inhaled powder, metered-dose inhaler, dry powder inhaler, nebulizer)
Industry: Biotech

Beyond the preview

Go deeper on Shenzhen Resproly Biopharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shenzhen Resproly Biopharmaceutical.

Explore the full profile